Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1677
    +0.0021 (+0.18%)
     

  • GBP/USD

    1.2495
    -0.0016 (-0.13%)
     

  • Bitcoin GBP

    51,189.14
    -445.33 (-0.86%)
     

  • CMC Crypto 200

    1,332.20
    -64.34 (-4.61%)
     

  • S&P 500

    5,102.86
    +54.44 (+1.08%)
     

  • DOW

    38,271.37
    +185.57 (+0.49%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • GOLD FUTURES

    2,351.80
    +9.30 (+0.40%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

Zacks Equity Research
Updated

Novo Nordisk NVO announced that Health Canada has approved Ozempic (semaglutide injection) to improve glycemic control in adults with type II diabetes mellitus, when metformin is not tolerated or contraindicated. Ozempic, a once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist, can also be used together with other antidiabetic drugs when diet and exercise do not achieve adequate glycemic control.

Shares of the company have rallied 52.4% compared with the industry’s gain of 16.8% in the past year.

The approval of Ozempic was based on results from the phase III SUSTAIN study. The results showed that people with type II diabetes, who are treated with once-weekly semaglutide, experienced statistically significant and sustained blood glucose control compared with Merck’s MRK Januvia (sitagliptin), Astrazeneca’s AZN once-weekly Bydureon (exenatide extended-release), Sanofi’s SNY Lantus (insulin glargine) and placebo.

ADVERTISEMENT

In December 2017, the FDA approved Ozempic once-daily pre-filled pen to improve glycaemic control in type II diabetes patients. European regulatory authorities also adopted a positive opinion, recommending marketing authorization for Ozempicon Dec 15.

Additionally, Novo Nordisk is making efforts to develop new treatments for diabetes, which is its core area of expertise. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp. Other than semaglutide, its key pipeline candidate includes nonacog beta pegol. 

The approval of the drug will give a boost to the company’s revenues.

Novo Nordisk A/S Price

 

Novo Nordisk A/S Price | Novo Nordisk A/S Quote

Zacks Rank

Novo Nordisk carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Sanofi (SNY) : Free Stock Analysis Report
 
Astrazeneca PLC (AZN) : Free Stock Analysis Report
 
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
 
Merck & Company, Inc. (MRK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research